Zacks Investment Research downgraded AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) to Hold in a report released today.
- Updated: October 11, 2016
Zacks Investment Research has downgraded AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) to Hold in a report released on 10/11/2016.
Previously on 8/15/2016, Zacks Investment Research released a statement about AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) increased the target price from $0.00 to $4.00. At the time, this indicated a possible upside of 0.09%.
Just yesterday AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) traded 3.89% higher at $3.47. AEterna Zentaris Inc. (USA)’s 50-day moving average is $3.51 and its 200-day moving average is $3.54. The last stock price is down -1.94% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 178,478 shares of AEZS traded hands, up from an average trading volume of 99,149
Recent Performance Chart
AEterna Zentaris Inc. (USA) has 52 week low of $2.60 and a 52 week high of $15.70 and has a market capitalization of $0.
Brief Synopsis On AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)
Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.